Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Edoxaban Versus Apixaban in Cancer-Associated Venous Thromboembolism (NEXT-CAT)

25. september 2026 oppdatert av: Eun Kyoung Kim, Samsung Medical Center

Net Adverse Clinical Events With EdoXaban Versus Apixaban Treatment in Cancer-Associated Thrombosis

This prospective, multicenter, randomized, open-label, blinded-endpoint trial aims to compare the clinical efficacy and safety of edoxaban-based treatment versus apixaban-based treatment in patients with cancer-associated venous thromboembolism (CAT). A total of 2,300 patients with active cancer and objectively confirmed venous thromboembolism will be randomized in a 1:1 ratio to receive edoxaban-based or apixaban-based treatment. The primary objective is to determine whether edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to net adverse clinical events (NACE), defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria.

Studieoversikt

Status

Har ikke rekruttert ennå

Detaljert beskrivelse

Cancer-associated thrombosis (CAT) is an important cause of morbidity and mortality in patients with active cancer. Patients with CAT are at increased risk of both recurrent venous thromboembolism and bleeding during anticoagulant treatment, making the balance between efficacy and safety particularly important when selecting an anticoagulant.

Non-vitamin K antagonist oral anticoagulants have become established treatment options for CAT. Edoxaban and apixaban are both factor Xa inhibitors with demonstrated efficacy and safety in patients with CAT. However, they have been evaluated separately against low-molecular-weight heparin, and direct randomized comparisons between edoxaban and apixaban are lacking. The two agents also differ in dosing frequency, dose-reduction strategies, pharmacokinetic characteristics, and renal elimination. Whether these differences translate into differences in overall clinical outcomes in patients with CAT remains uncertain.

NEXT-CAT is a prospective, multicenter, randomized, open-label, blinded-endpoint trial designed to directly compare edoxaban-based treatment with apixaban-based treatment in patients with active cancer and objectively confirmed venous thromboembolism. A total of 2,300 participants will be randomized in a 1:1 ratio, with randomization stratified by participating center and the presence of gastrointestinal cancer at baseline.

The primary hypothesis is that edoxaban-based treatment is non-inferior to apixaban-based treatment with respect to the incidence of net adverse clinical events (NACE). The primary endpoint is a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis criteria. Participants will be followed at 1, 3, 6, 9, 12, and 18 months after randomization and annually thereafter, with follow-up continuing until 1 year after enrollment of the last participant.

Clinical events corresponding to the primary and secondary endpoints will be evaluated by an independent Clinical Event Adjudication Committee blinded to treatment allocation.

Studietype

Intervensjonell

Registrering (Antatt)

2300

Fase

  • Fase 4

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Busan, Sør -Korea
        • Dong-A University Hospital
        • Ta kontakt med:
          • Sung-Hyun Kim
        • Hovedetterforsker:
          • Sung-Hyun Kim, MD, PhD
      • Goyang, Sør -Korea
        • Inje University Ilsan Paik Hospital
        • Ta kontakt med:
          • Min Sun Kim
        • Hovedetterforsker:
          • Min Sun Kim
      • Gwangmyeong, Sør -Korea
        • Chung-Ang University Gwangmyeong Hospital
        • Ta kontakt med:
          • Eun Jeong Cho
        • Hovedetterforsker:
          • Eun Jeong Cho
      • Hwasun, Sør -Korea
        • Chonnam National University Hwasun Hospital
        • Ta kontakt med:
          • Hyukjin Park
        • Hovedetterforsker:
          • Hyukjin Park
      • Jeonju, Sør -Korea
        • Chonbuk National University Hospital
        • Ta kontakt med:
          • Ho-Young Yhim
        • Hovedetterforsker:
          • Ho-Young Yhim, MD, PhD
      • Seoul, Sør -Korea
        • Kangbuk Samsung Hospital
        • Ta kontakt med:
          • Jiwon Kim
        • Hovedetterforsker:
          • Jiwon Kim
      • Seoul, Sør -Korea
        • Korea University Anam Hospital
        • Ta kontakt med:
          • So Ree Kim
        • Hovedetterforsker:
          • So Ree Kim
      • Seoul, Sør -Korea
        • Samsung Medical Center
        • Underetterforsker:
          • Se-Hoon Lee, MD, PhD
        • Underetterforsker:
          • Taek Kyu Park, MD, PhD
        • Ta kontakt med:
        • Hovedetterforsker:
          • Eun Kyoung Kim, MD, PhD
        • Underetterforsker:
          • David Hong, MD, PhD
      • Seoul, Sør -Korea
        • Seoul National University Hospital
        • Ta kontakt med:
          • Sang-Hoon Na, MD, PhD
        • Hovedetterforsker:
          • Sang-Hoon Na, MD, PhD
      • Seoul, Sør -Korea
        • Konkuk University Medical Center
        • Ta kontakt med:
          • Ji-Won Hwang
        • Hovedetterforsker:
          • Ji-Won Hwang
      • Seoul, Sør -Korea
        • Seoul St. Mary's Hospital
        • Ta kontakt med:
          • Mi-Hyang Jung
        • Hovedetterforsker:
          • Mi-Hyang Jung, MD, PhD
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, Sør -Korea
        • National Cancer Center
        • Ta kontakt med:
          • Mi-Hyang Kwak
        • Hovedetterforsker:
          • Mi-Hyang Kwak

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

19 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  1. Age ≥19 years.

  2. Objectively confirmed symptomatic or incidentally detected venous thromboembolism (VTE), including:

    • Proximal deep vein thrombosis (DVT)
    • Pulmonary embolism (PE)
    • Both DVT and PE.
  3. Any type of active cancer, defined by at least one of the following:

    • Cancer diagnosed within the previous 6 months
    • Locally advanced or metastatic cancer
    • Receipt of cancer-directed therapy (chemotherapy, immunotherapy, targeted therapy, endocrine therapy, radiotherapy, or cancer surgery) within the previous 6 months
    • Cancer not in complete remission at the time of enrollment
    • Ongoing cancer treatment or residual cancer.
  4. Ability to understand the risks, benefits, and treatment alternatives of the study and to voluntarily provide written informed consent.

Exclusion Criteria:

  1. Known hypersensitivity or contraindication to either study drug (edoxaban or apixaban).
  2. Severe renal impairment (creatinine clearance <15 mL/min) or dialysis.
  3. Active major bleeding.
  4. An indication requiring alternative anticoagulation, such as a mechanical heart valve or moderate-to-severe mitral stenosis.
  5. Antiphospholipid syndrome.
  6. Life expectancy <6 months due to cancer progression or comorbid conditions, or anticipated poor treatment adherence, as determined by the investigator.
  7. Pregnancy or breastfeeding.
  8. Moderate or severe hepatic impairment classified as Child-Pugh class B or C.
  9. Thrombocytopenia with a platelet count <50,000/mm³.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: Edoxaban-based Treatment

Participants randomized to this arm will receive oral edoxaban once daily. The standard dose is 60 mg once daily, with dose reduction according to the protocol based on renal function, body weight, concomitant P-glycoprotein inhibitors, and other prespecified clinical factors.

Edoxaban is administered orally once daily. The standard dose is 60 mg once daily. The dose is reduced to 30 mg once daily in participants with a creatinine clearance of 15-50 mL/min, body weight ≤60 kg, or concomitant use of specified P-glycoprotein inhibitors. In participants aged ≥80 years who are considered at high risk of bleeding and meet the prespecified criteria, further dose reduction to 15 mg once daily may be considered.

Aktiv komparator: Apixaban-based Treatment

Participants randomized to this arm will receive oral apixaban twice daily. The standard dose is 5 mg twice daily, with dose reduction to 2.5 mg twice daily according to the prespecified dose-reduction criteria in the protocol.

Apixaban is administered orally at a standard dose of 5 mg twice daily. The dose is reduced to 2.5 mg twice daily in participants who meet the prespecified dose-reduction criteria, including those who meet at least two of the following criteria: age ≥80 years, body weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, or those with severe renal impairment with a creatinine clearance of 15-29 mL/min.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Net Adverse Clinical Events (NACE)
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, or major bleeding according to the International Society on Thrombosis and Haemostasis (ISTH) criteria.

From randomization until 1 year after enrollment of the last participant

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Recurrent Venous Thromboembolism or Venous Thromboembolism-related Death
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of recurrent venous thromboembolism or venous thromboembolism-related death.

From randomization until 1 year after enrollment of the last participant
Recurrent Venous Thromboembolism
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of objectively confirmed recurrent venous thromboembolism, including recurrent deep vein thrombosis or recurrent pulmonary embolism.

From randomization until 1 year after enrollment of the last participant
Venous Thromboembolism-related Death
Tidsramme: From randomization until 1 year after enrollment of the last participant

Death resulting from objectively confirmed fatal pulmonary embolism, recurrent venous thromboembolism directly leading to death, or unexplained death for which no alternative cause is identified and which is adjudicated as venous thromboembolism-related by the Clinical Event Adjudication Committee.

From randomization until 1 year after enrollment of the last participant
Major Bleeding According to International Society on Thrombosis and Haemostasis Criteria
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of major bleeding according to International Society on Thrombosis and Haemostasis criteria, including fatal bleeding, symptomatic bleeding in a critical area or organ, bleeding causing a decrease in hemoglobin of at least 2 g/dL, or bleeding requiring transfusion of at least 2 units of whole blood or packed red blood cells.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Non-major Bleeding
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant non-major bleeding, defined as clinically overt bleeding that does not meet the criteria for major bleeding but leads to hospitalization or an increased level of care, medical or surgical treatment, or a change in antithrombotic therapy.

From randomization until 1 year after enrollment of the last participant
Clinically Relevant Bleeding
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of clinically relevant bleeding, defined as a composite of major bleeding or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
Broad Net Adverse Clinical Events
Tidsramme: From randomization until 1 year after enrollment of the last participant

Time to the first occurrence of a broad net adverse clinical event, defined as a composite of recurrent venous thromboembolism, venous thromboembolism-related death, major bleeding, or clinically relevant non-major bleeding.

From randomization until 1 year after enrollment of the last participant
All-cause Mortality
Tidsramme: From randomization until 1 year after enrollment of the last participant

Death due to any cause occurring during the study follow-up period.

From randomization until 1 year after enrollment of the last participant
Permanent Discontinuation Due to Adverse Events
Tidsramme: From randomization until 1 year after enrollment of the last participant

Permanent discontinuation of the assigned study drug due to any adverse event during follow-up.

From randomization until 1 year after enrollment of the last participant

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

1. november 2026

Primær fullføring (Antatt)

31. desember 2029

Studiet fullført (Antatt)

31. desember 2030

Datoer for studieregistrering

Først innsendt

25. september 2026

Først innsendt som oppfylte QC-kriteriene

25. september 2026

Først lagt ut (Faktiske)

1. oktober 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

1. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

25. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

De-identified individual participant data that underlie the results reported in the main publication may be shared with qualified researchers upon reasonable request.

IPD-delingstidsramme

Beginning after publication of the main study results; no predetermined end date.

Tilgangskriterier for IPD-deling

Data may be made available to qualified researchers upon reasonable request for scientifically appropriate research purposes. Requests will be reviewed by the principal investigator and the study steering committee based on the scientific merit and appropriateness of the proposed research and data-use plan. Data sharing will be conducted in accordance with applicable regulations and participant privacy requirements.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere